In a similar research strategy, aptamer based CD16/programmed death ligand 1 (PD-L1) bispecific molecules have been successfully constructed, which exhibit significant anti-tumor synergistic effects through a dual mechanism of synergistic activation of NK cell recruitment and PD-L1 immune checkpoint blockade (12). This evidence concerns the gene CD274 and neoplasm.